Objective
Re-evaluate PRODUCT X’s pricing and market access (P&MA) opportunity and develop the optimal launch strategy across four pipeline indications in each in-scope market.
Scope
Methodology
Capture latest thinking on P&MA expectations for PRODUCT X from local affiliates (LOCs) and align on the priorities for primary research. Collect key insights from payer stakeholders through telephone-depth interviews (TDIs) to pressure test updated target product profiles (TPPs) and P&MA assumptions. Provide synthesized insights into PRODUCT X opportunity across its life cycle management indication expansions.
Deliverables
- Local affiliates engagement to facilitate insight collection.
- Country-specific moderator guides and research stimuli.
- Country-specific overview of current and future indication specific treatment dynamics and P&MA landscape.
- Indication launch optimization and P&MA recommendations for PRODUCT X
Illustrative Outputs
Impact
CBP provided pricing and market access guidance across a range of hematology-oncology indications and markets, informing optimization of life-cycle management (LCM) expansion activities.